Purple Biotech Ltd (KTOV) fair value: what the stock is really worth
As of Sep 28, 2026: fair value of Purple Biotech Ltd ILS 0.02, price ILS 0.01, upside +60.0%, quality 44 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 4, 2026.
How to read this chart
60‑month range 0.0100 ILA – 2.13 ILA · fair‑value band 0.0140 ILA – 0.0180 ILA · the 0.0100 ILA price screens below the 0.0160 ILA fair value. Dashed = 300-day average. As of Oct 4, 2026.
Follow Purple Biotech in your weekly email
Every Wednesday you see whether Purple Biotech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension.
Show more
Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension in the United States, as well as in China and South Korea. Its oncology pipeline includes NT-219, a small molecule that is advancing as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer in a planned phase 1/2 study; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech Ltd. is headquartered in Tel Aviv, Israel.
Stock analysis
Purple Biotech Ltd (KTOV) currently trades at 0.0100 ILA, while our model-based Fair Value estimate is 0.0160 ILA, implying the stock looks roughly 37.5% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 84/100, which puts the evidence level at low.
Scenario range: 0.0140 ILA (bear) to 0.0180 ILA (bull), the price of 0.0100 ILA sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Purple Biotech Ltd reported revenue of $1.0M in FY2019 versus $0 in FY2015. Reported net income was −$5.9M in FY2019.
Key figures
Market cap 227M ILA · EPS (TTM) −0.1660 ILA · Return on equity −92.0% · Return on assets (EBIT) −56.3% · Operating margin −754% · Revenue (TTM) $1.0M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 25 out of 100 (low confidence).
What moves the price
The share trades about 41% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −34% fair-value upside, at 60%, KTOV screens cheaper than that median.
Fair Value models
Bear 0.0140 ILAFair Value 0.0160 ILABull 0.0180 ILA
Price 0.0100 ILA · Upside +60.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is weak, negative or inconsistent.
Revenue growth 1 year
+0.0%
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.2%
’08
’09
’10
’11
’12
’17
’18
’19
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Biotechnology & Medical Research” was too small, so the broader sector is used.)Health Care · 2375 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Purple Biotech Ltd (KTOV) overvalued or undervalued?
As of Oct 4, 2026, our model estimates a fair value of 0.0160 ILA versus the last price from Sep 28, 2026 of 0.0100 ILA, about +60% upside (undervalued).
What is the fair value of KTOV?
Our model-based fair value for Purple Biotech Ltd is 0.0160 ILA (as of Oct 4, 2026), built from audited fundamentals. Last price (from Sep 28, 2026): 0.0100 ILA.
What is the quality score of KTOV?
Purple Biotech Ltd has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Purple Biotech Ltd (KTOV)?
Our model-based price target is the fair value of 0.0160 ILA (as of Oct 4, 2026) from 1 valuation models. Cautious scenario 0.0140 ILA, optimistic scenario 0.0180 ILA. It is a calculation from audited fundamentals, not an analyst target.
What is the Purple Biotech Ltd stock forecast for 2026?
Our models put fair value at 0.0160 ILA, about +60% upside versus the last price from Sep 28, 2026 of 0.0100 ILA (undervalued). Cautious scenario 0.0140 ILA, optimistic scenario 0.0180 ILA. The calculation is refreshed regularly with new filings.
What is the revenue of Purple Biotech Ltd (KTOV)?
Purple Biotech Ltd reported trailing-twelve-month revenue of about $1.0M (latest available figure, as of Oct 4, 2026).
What is the intrinsic value of Purple Biotech Ltd (KTOV)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Purple Biotech Ltd it is 0.0160 ILA per share (as of Oct 4, 2026), against a price of 0.0100 ILA. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Purple Biotech Ltd stock overvalued or undervalued in 2026?
As of Oct 4, 2026, KTOV trades below its calculated fair value: price 0.0100 ILA, fair value 0.0160 ILA, a gap of about +60% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of KTOV?
No. The price is what the market pays today (0.0100 ILA); the fair value is what the company's own numbers justify (0.0160 ILA). For Purple Biotech Ltd the two are 0.0060 ILA per share apart. That gap is exactly why we show both numbers side by side.
How much is Purple Biotech Ltd worth?
The market values Purple Biotech Ltd at about 227M ILA (market capitalisation, as of Oct 4, 2026). Per share that is 0.0100 ILA; our models calculate a fair value of 0.0160 ILA per share.
What do the bullish and bearish scenarios say about KTOV?
Our models span a range for Purple Biotech Ltd: cautious scenario 0.0140 ILA, base 0.0160 ILA, optimistic 0.0180 ILA per share (as of Oct 4, 2026, price 0.0100 ILA). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Purple Biotech Ltd (KTOV)?
Balance-sheet figures for Purple Biotech Ltd (as of Oct 4, 2026): return on equity −92.0%, debt of 0.10 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is KTOV from its 52-week high?
Purple Biotech Ltd trades at 0.0100 ILA, about 41% below its 52-week high of 0.0170 ILA and at the low of 0.0100 ILA (as of Sep 28, 2026). Distance from the high says nothing about value: that is what the fair value of 0.0160 ILA is for.
Which stocks are comparable to Purple Biotech Ltd?
From the same area (Healthcare) we also value MEDIPOST Co, Bioneer Corporation, Macrogen, Inc, Cell Biotech Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Purple Biotech Ltd stock attractive at the current price?
The data as of Oct 4, 2026: price 0.0100 ILA, calculated fair value 0.0160 ILA (+60%), Quality Score 44/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of KTOV calculated?
We run Purple Biotech Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.0160 ILA, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Purple Biotech Ltd currently trades 38 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Purple Biotech Ltd (KTOV)?
The latest price we hold is from Sep 28, 2026 and stands at 0.0100 ILA. Our model-based fair value is 0.0160 ILA, about +60% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Purple Biotech Ltd right now?
The large discount to fair value meets weak quality (44/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (0.0140 ILA). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Purple Biotech Ltd
How large is the market capitalisation of Purple Biotech Ltd (KTOV)?
The market capitalisation of Purple Biotech Ltd is 227M ILA. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Purple Biotech Ltd (KTOV)?
Earnings per share at Purple Biotech Ltd are −0.1660 ILA. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Purple Biotech Ltd (KTOV)?
The return on equity (ROE) of Purple Biotech Ltd is −92.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Purple Biotech Ltd (KTOV)?
On an EBIT basis the return on assets of Purple Biotech Ltd is −56.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Purple Biotech Ltd (KTOV)?
The operating margin of Purple Biotech Ltd is −754% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
Free · no account needed
Watch Purple Biotech Ltd in the live analysis
One click puts Purple Biotech Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
